消化

订阅

MedSci主页 / 所有栏目 / 消化

2型糖尿病和非酒精性脂肪肝的新型治疗分子

2019-04-11 不详 网络

非酒精性脂肪肝2型糖尿病EPB-53
关注

巴塞罗那大学（IBUB）糖尿病和相关代谢疾病网络生物医学研究中心（CIBERDEM）的研究人员近日发现了一种新型分子EPB-53，并证明其可以帮助对抗2型糖尿病和非酒精性脂肪肝。

巴塞罗那大学（IBUB）糖尿病和相关代谢疾病网络生物医学研究中心（CIBERDEM）的研究人员近日发现了一种新型分子EPB-53，并证明其可以帮助对抗2型糖尿病和非酒精性脂肪肝。

成纤维细胞生长因子21（FGF21）是一种内分泌因子，在糖尿病和能量代谢障碍中具有决定性作用。这种主要由肝脏合成的因子被认为是治疗2型糖尿病和非酒精性脂肪肝的潜在治疗靶点。根据临床前研究，口服EPB-53分子可以增加肝脏和血浆中FGF21的水平。EPB-53是一种激活HRI（由血红素基因调节的eIF2α激酶）的分子，HRI可以促进FGF21的转录因子，从而降低小鼠的葡萄糖耐量和肝脂肪变性。


原始出处：

http://www.firstwordpharma.com/node/1634455#axzz5kmtmGZrh

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1980504, encodeId=e7a719805046e, content=<a href='/topic/show?id=099f9548ed7' target=_blank style='color:#2F92EE;'>#酒精性脂肪肝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95487, encryptionId=099f9548ed7, topicName=酒精性脂肪肝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri Sep 20 18:14:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1673483, encodeId=235916e348307, content=<a href='/topic/show?id=757b954e922' target=_blank style='color:#2F92EE;'>#酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95479, encryptionId=757b954e922, topicName=酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=398f26933958, createdName=huiwelcome, createdTime=Mon Dec 30 22:14:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676477, encodeId=814116e64770a, content=<a href='/topic/show?id=397299e19c7' target=_blank style='color:#2F92EE;'>#非酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99719, encryptionId=397299e19c7, topicName=非酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d18c27357544, createdName=Tommy1958, createdTime=Tue Mar 24 21:14:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042375, encodeId=4ea310423e5b9, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Apr 11 23:14:00 CST 2019, time=2019-04-11, status=1, ipAttribution=)]
    2019-09-20 yangshch

    #酒精性脂肪肝#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1980504, encodeId=e7a719805046e, content=<a href='/topic/show?id=099f9548ed7' target=_blank style='color:#2F92EE;'>#酒精性脂肪肝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95487, encryptionId=099f9548ed7, topicName=酒精性脂肪肝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri Sep 20 18:14:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1673483, encodeId=235916e348307, content=<a href='/topic/show?id=757b954e922' target=_blank style='color:#2F92EE;'>#酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95479, encryptionId=757b954e922, topicName=酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=398f26933958, createdName=huiwelcome, createdTime=Mon Dec 30 22:14:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676477, encodeId=814116e64770a, content=<a href='/topic/show?id=397299e19c7' target=_blank style='color:#2F92EE;'>#非酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99719, encryptionId=397299e19c7, topicName=非酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d18c27357544, createdName=Tommy1958, createdTime=Tue Mar 24 21:14:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042375, encodeId=4ea310423e5b9, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Apr 11 23:14:00 CST 2019, time=2019-04-11, status=1, ipAttribution=)]
    2019-12-30 huiwelcome

    #酒精性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1980504, encodeId=e7a719805046e, content=<a href='/topic/show?id=099f9548ed7' target=_blank style='color:#2F92EE;'>#酒精性脂肪肝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95487, encryptionId=099f9548ed7, topicName=酒精性脂肪肝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri Sep 20 18:14:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1673483, encodeId=235916e348307, content=<a href='/topic/show?id=757b954e922' target=_blank style='color:#2F92EE;'>#酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95479, encryptionId=757b954e922, topicName=酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=398f26933958, createdName=huiwelcome, createdTime=Mon Dec 30 22:14:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676477, encodeId=814116e64770a, content=<a href='/topic/show?id=397299e19c7' target=_blank style='color:#2F92EE;'>#非酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99719, encryptionId=397299e19c7, topicName=非酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d18c27357544, createdName=Tommy1958, createdTime=Tue Mar 24 21:14:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042375, encodeId=4ea310423e5b9, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Apr 11 23:14:00 CST 2019, time=2019-04-11, status=1, ipAttribution=)]
    2020-03-24 Tommy1958

    #非酒精性#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1980504, encodeId=e7a719805046e, content=<a href='/topic/show?id=099f9548ed7' target=_blank style='color:#2F92EE;'>#酒精性脂肪肝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95487, encryptionId=099f9548ed7, topicName=酒精性脂肪肝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26a9200, createdName=yangshch, createdTime=Fri Sep 20 18:14:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1673483, encodeId=235916e348307, content=<a href='/topic/show?id=757b954e922' target=_blank style='color:#2F92EE;'>#酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95479, encryptionId=757b954e922, topicName=酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=398f26933958, createdName=huiwelcome, createdTime=Mon Dec 30 22:14:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676477, encodeId=814116e64770a, content=<a href='/topic/show?id=397299e19c7' target=_blank style='color:#2F92EE;'>#非酒精性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99719, encryptionId=397299e19c7, topicName=非酒精性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d18c27357544, createdName=Tommy1958, createdTime=Tue Mar 24 21:14:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042375, encodeId=4ea310423e5b9, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Apr 11 23:14:00 CST 2019, time=2019-04-11, status=1, ipAttribution=)]
    2019-04-11 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Lancet Gastroen Hepatol：亚洲非酒精性脂肪肝流行病学研究

研究发现，非酒精性脂肪肝在亚洲的流行率正在上升，并与肝细胞性肝癌和死亡等不良后果有关

Curr Pharm Des：他汀类药物在非酒精性脂肪性肝病治疗中的作用

在线发表于《Curr Pharm Des》杂志上的一项综述指出，非酒精性脂肪性肝病（NAFLD）及其晚期非酒精性脂肪性肝炎（NASH）患者有较高的CVD风险，服用他汀类药物和普通人群一样安全，可以选择一种特定的他汀类药物（阿托伐他汀）来显著减少肝脏和CVD相关的不良事件。

Intercept公司的奥贝胆酸即将成为第一个获批的非酒精性脂肪性肝炎（NASH）药物

临床数据显示，与安慰剂相比，在18个月的随访后，在10mg和25mg剂量水平下，奥贝胆酸obeticholic acid能够改善肝纤维化。

BCPT：GLP-1受体激动剂除了降糖，还能护肝，专家怎么看？

丹麦哥本哈根大学David H. Ipsen教授团队在Basic & Clinical Pharmacology & Toxicology发表的一项基础研究，评估了利拉鲁肽和饮食干预，单独或联合对高脂饮食喂养导致的非肥胖的非酒精性脂肪性肝炎（NASH）豚鼠的作用。

内源性代谢调节剂AXA1125作为非酒精性脂肪肝候选药，临床数据证实调节肝脏代谢、炎症和纤维化

从体内外结果和IRB批准的临床研究表明AXA1125：降低人肝细胞中的甘油三酯； 抑制有氧糖酵解，同时保留人巨噬细胞中的总ATP水平； 减少ProC3和其他关键纤维化标志物，包括减少人类星状细胞的活化和增殖。

PLOS ONE：西方饮食诱导的非酒精性脂肪性肝炎的脂质组学和转录组学分析

非酒精性脂肪性肝病（NAFLD）是世界上最常见的慢性肝病，特别是在肥胖和2型糖尿病患者中。 NAFLD的严重程度范围可以从良性脂肪变性到非酒精性脂肪性肝炎（NASH），NASH还可以发展为肝硬化，原发性肝细胞癌（HCC）和肝功能衰竭。因此，NAFLD已成为一个主要的公共卫生问题。